menu
    • menu

    Company profile for Shanghai Hengrui Pharmaceutical

    NEW Drugs in Dev: 35
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Shanghai Hengrui Medicine Co., Ltd. is a joint venture established by Jiangsu Hengrui Medicine Co., Ltd. and Hong Kong Hongchuang Technology Co., Ltd., with a registered capital of 72 million yuan. The company is located in Shanghai Minhang Economic and Technological Development Zone, covering an area of ​​80 acres, with a high-level scientific research and experimental base and a high-level GMP production workshop.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Shanghai Hengrui PharmaceuticalChina Flag
    Country
    Country
    China
    Address
    Address
    No. 279, Wenjing Road, Economic and Technological Development Zone, Minhang Di...
    Telephone
    Telephone
    +86-2123511999
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.shhrp.com/contact.html
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hengrui Pharma, Kailera Therapeutics Present Clinical Data
    Hengrui Pharma, Kailera Therapeutics Present Clinical Data

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3293890/0/en/hengrui-pharma-and-kailera-therapeutics-announce-clinical-data-presentations-at-the-american-diabetes-association-86th-scientific-sessions.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Hengrui Pharma's Q1 2026 Profit Meets Expectations
    Hengrui Pharma's Q1 2026 Profit Meets Expectations

    22 Apr 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-top-drugmaker-hengrui-profit-line-with-expectations-first-quarter-2026-2026-04-22/

    REUTERS
    22 Apr 2026
    Share Share
    Glenmark, Hengrui ink $1.1B deal for HER2 ADC
    Glenmark, Hengrui ink $1.1B deal for HER2 ADC

    24 Sep 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/potential-11b-deal-glenmark-grabs-certain-rights-hengrui-adc-rival-enhertu

    FIERCE PHARMA
    24 Sep 2025
    Share Share
    Jiangsu Hengrui Grants GSK global rights to Drug portfolio
    Jiangsu Hengrui Grants GSK global rights to Drug portfolio

    29 Jul 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/jiangsu-hengrui-grants-gsk-global-rights-drug-portfolio-500-million-deal-2025-07-28/

    REUTERS
    29 Jul 2025
    Share Share
    IDEAYA, Hengrui to Present IDE849 (SHR-4849) Data at IASLC 2025
    IDEAYA, Hengrui to Present IDE849 (SHR-4849) Data at IASLC 2025

    22 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-and-hengrui-pharmaceuticals-announce-oral-presentation-at-iaslc-2025-world-conference-on-lung-cancer-for-ide849-shr-4849-a-potential-first-in-class-dll3-top1-adc-302510323.html

    PR NEWSWIRE
    22 Jul 2025
    Share Share
    Hengrui Pharma Highlights Chinese Cancer Innovation at 2025 ASCO
    Hengrui Pharma Highlights Chinese Cancer Innovation at 2025 ASCO

    05 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hengrui-pharma-showcases-global-impact-at-the-2025-asco-72-study-results-highlight-chinese-cancer-innovation-302474128.html

    PR NEWSWIRE
    05 Jun 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search